Cash Flow Forecast. During the Waiver Period, the following: (i) by no later than 5:00 pm New York time on Friday of each week (or on such other day or at such other time as the Collateral Agent (acting on the instructions of the Lenders) may agree), a weekly rolling 13-week cash flow forecast relating to the liquidity needs of Issuer and its Subsidiaries with accompanying variance analysis and commentary in the format and prepared on the basis of the latest 13-week cash flow forecasts provided by the Credit Parties to the Collateral Agent on the Ninth Amendment Effective Date; (ii) as soon as reasonably practicable, any information provided by Issuer or any of its Subsidiaries to any lender or creditor (howsoever described), or any information, notices or requests received by Issuer or any of its Subsidiaries from any lender or creditor (howsoever described), in each case, under (i) the Indenture, dated as of March 3, 2022, between LumiraDx Limited, as issuer and U.S. Bank Trust Company, National Association, as trustee, (ii) the Royalty Agreement or (iii) the Note Purchase Agreement, dated as of October 17, 2019, by and between LumiraDx Limited and the Bill & ▇▇▇▇▇▇▇ ▇▇▇▇▇ Foundation of PO Box 23350, Seattle, WA, as purchaser.
Appears in 2 contracts
Sources: Twelfth Amendment and Waiver (LumiraDx LTD), Ninth Amendment and Waiver (LumiraDx LTD)
Cash Flow Forecast. During the Waiver Period, the following:
(i) by no later than 5:00 pm New York time on Friday of each week (or on such other day or at such other time as the Collateral Agent (acting on the instructions of the Lenders) may agree), a weekly rolling 13-week cash flow forecast relating to the liquidity needs of Issuer and its Subsidiaries with accompanying variance analysis and commentary in the format and prepared on the basis of the latest 13-week cash flow forecasts provided by the Credit Parties to the Collateral Agent on the Ninth Amendment Effective Date;
(ii) as soon as reasonably practicable, any information provided by Issuer or any of its Subsidiaries to any lender or creditor (howsoever described), or any information, notices or requests received by Issuer or any of its Subsidiaries from any lender or creditor (howsoever described), in each case, under (i) the Indenture, dated as of March 3, 2022, between LumiraDx Limited, as issuer and U.S. Bank Trust Company, National Association, as trustee, (ii) the Royalty Agreement or (iii) the Note Purchase Agreement, dated as of October 17, 2019, by and between LumiraDx Limited and the Bill & ▇M▇▇▇▇▇▇ ▇▇▇▇▇ Foundation of PO Box 23350, Seattle, WA, as purchaser.
Appears in 1 contract
Sources: Fifteenth Amendment (LumiraDx LTD)